|
KMID : 1161420210240020111
|
|
Journal of Medicinal Food
2021 Volume.24 No. 2 p.111 ~ p.115
|
|
|
Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial
|
|
Leon-Martinez Juan M.
Martinez-Abundis Esperanza
Gonzalez-Ortiz Manuel
Perez-Rubio Karina G.
|
|
|
Abstract
|
|
|
|
To evaluate the effect of berberine (BBR) plus bezafibrate administration on the lipid profile of patients with mixed dyslipidemia. A double-blind randomized pilot clinical trial with parallel groups was carried out in 36 patients, aged 30?60 years with mixed dyslipidemia [triglycerides (TG) ≥1.7?mM and total cholesterol (TC) ≥5.2?mM]. Patients were assigned to 3 groups of 12 patients each, receiving oral administration during 90 days of BBR 500?mg t.i.d., bezafibrate 400?mg b.i.d., or BBR 500?mg t.i.d. plus bezafibrate 400?mg b.i.d, respectively. Clinical evaluation, lipid profile, glucose, creatinine, and uric acid levels were measured before and after the pharmacological intervention. Kruskal?Wallis, Wilcoxon, Mann?Whitney U, and χ2 tests were used for statistical analyses; a P?≤?.05 was considered statistically significant. BBR reduced TC levels. Bezafibrate decreased TG, TC, low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein (VLDL) concentrations. BBR plus bezafibrate decreased TG (2.6?±?0.8 vs. 1.3?±?0.7?mM, P?=?.007), TC (6.3?±?0.7 vs. 4.6?±?1.2?mM, P?=?.005), LDL-C (3.4?±?0.6 vs. 2.2?±?1.3?mM, P?=?.037), and VLDL (0.5?±?0.2 vs. 0.2?±?0.1?mM, P?=?.007) levels. Bezafibrate and BBR plus bezafibrate significantly decreased TG, TC, LDL-C, and VLDL concentrations, and thus, remitting the diagnosis of mixed dyslipidemia in 90% of the patients.
|
|
|
KEYWORD
|
|
|
berberine, bezafibrate, lipids, mixed dyslipidemia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|